Latamoxef | CAS#64952-97-2

MedKoo Cat#: 318088 | Name: Latamoxef

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Latamoxef is an oxacephem antibiotic usually grouped with the cephalosporins.

Chemical Structure

Latamoxef

CAS#64952-97-2 (free acid)

Theoretical Analysis

MedKoo Cat#: 318088

Name: Latamoxef

CAS#: 64952-97-2 (free acid)

Chemical Formula: C20H20N6O9S

Exact Mass: 520.1012

Molecular Weight: 520.47

Elemental Analysis: C, 46.15; H, 3.87; N, 16.15; O, 27.67; S, 6.16

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

64953-12-4 (sodium) 64952-97-2 (free acid)

Synonym

Latamoxef, Moxalactam, Lamoxactam, Festamoxin, 6059-S

IUPAC/Chemical Name

(6R,7R)-7-[[2-carboxy-2-(4-hydroxyphenyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

InChi Key

JWCSIUVGFCSJCK-CAVRMKNVSA-N

InChi Code

InChI=1S/C20H20N6O9S/c1-25-19(22-23-24-25)36-8-10-7-35-18-20(34-2,17(33)26(18)13(10)16(31)32)21-14(28)12(15(29)30)9-3-5-11(27)6-4-9/h3-6,12,18,27H,7-8H2,1-2H3,(H,21,28)(H,29,30)(H,31,32)/t12?,18-,20+/m1/s1

SMILES Code

O=C(C(N12)=C(CSC3=NN=NN3C)CO[C@]2([H])[C@](OC)(NC(C(C(O)=O)C4=CC=C(O)C=C4)=O)C1=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 520.47 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Hagiya H, Tasaka K, Sendo T, Otsuka F. Clinical ineffectiveness of latamoxef for Stenotrophomonas maltophilia infection. Infect Drug Resist. 2015 Oct 20;8:353-7. doi: 10.2147/IDR.S90726. eCollection 2015. PubMed PMID: 26527890; PubMed Central PMCID: PMC4621224. 2: Ito A, Tatsumi Y, Wajima T, Nakamura R, Tsuji M. Potent antibacterial activities of latamoxef (moxalactam) against ESBL producing Enterobacteriaceae analyzed by Monte Carlo simulation. Jpn J Antibiot. 2014 Apr;67(2):109-22. PubMed PMID: 24956910. 3: Gu HY, Sun DM, Yu AM, Chen HY. [Polarographic behavior of latamoxef sodium and its trace determination]. Yao Xue Xue Bao. 1997 May;32(5):373-6. Chinese. PubMed PMID: 11498875. 4: Chen YC, Hung CC, Lin SF, Chang SC, Hsieh WC. Comparison of flomoxef with latamoxef in the treatment of sepsis and/or Gram-negative bacteremia in adult patients. Int J Antimicrob Agents. 1996 May;7(1):69-74. PubMed PMID: 18611739. 5: Sotto A, Brunschwig C, O'Callaghan D, Ramuz M, Jourdan J. In-vitro evaluation of beta-lactamase inhibition by latamoxef and imipenem. J Antimicrob Chemother. 1996 Apr;37(4):697-701. PubMed PMID: 8722535. 6: Itoh M, Katoh N, Ono Y, Ohshima S, Miyake K. Sequential changes in the prostatic fluid level of latamoxef in patients with acute bacterial prostatitis. Urol Int. 1995;55(2):101-4. PubMed PMID: 8533190. 7: Oturai PS, Holländer NH, Hansen OP, Boas J, Bruun BG, Frimodt-Møller N, Dombernowsky P, Hansen HH. Ceftriaxone versus latamoxef in febrile neutropenic patients: empirical monotherapy in patients with solid tumours. Eur J Cancer. 1993;29A(9):1274-9. PubMed PMID: 8343267. 8: Katoh N, Ono Y, Ohshima S, Miyake K. Diffusion of cefmenoxime and latamoxef into prostatic fluid in the patients with acute bacterial prostatitis. Urol Int. 1992;48(2):191-4. PubMed PMID: 1585513. 9: Matsui K, Masuda N, Takada M, Kusunoki Y, Fukuoka M. A randomized trial comparing imipenem/cilastatine alone with latamoxef plus tobramycin in febrile neutropenic patients with lung cancer. Jpn J Clin Oncol. 1991 Dec;21(6):428-34. PubMed PMID: 1805048. 10: Bauernfeind A, Schweighart S, Eberlein E, Jungwirth R. In vitro activity and stability against novel beta-lactamases of investigational beta-lactams (cefepime, cefpirome, flomoxef, SCE2787 and piperacillin plus tazobactam) in comparison with established compounds (cefotaxime, latamoxef and piperacillin). Infection. 1991;19 Suppl 5:S264-75. PubMed PMID: 1664418. 11: Suzuki Y, Itoh S, Katoh M, Morita M, Fukushi Y, Toyota S, Katoh S, Oikawa K, Orikasa S, Majima K. [Clinical study concerning of latamoxef concentration in the obstructed urinary tract]. Hinyokika Kiyo. 1990 Aug;36(8):897-902. Japanese. PubMed PMID: 2173381. 12: Kouda M, Kumagai I, Kobayashi J, Sugai R, Matsuzaki H. [Combined effect of sulbactam/cefoperazone and other antibiotics against clinical isolates of multi-resistant strains. I. Effect of sulbactam against beta-lactams resistant strains and in vitro combined effect of sulbactam/cefoperazone with each of piperacillin, latamoxef, ceftazidime, fosfomycin and doxycycline]. Jpn J Antibiot. 1990 Apr;43(4):636-58. Japanese. PubMed PMID: 2199689. 13: Kitaura T, Tsukiai S, Arai S, Miyake K, Kimura M, Fukuchi H. Ocular pharmacokinetics of latamoxef and cefaclor in humans. Penetration into aqueous humor. J Pharmacobiodyn. 1989 Jan;12(1):60-6. PubMed PMID: 2724050. 14: Sugawara N, Hisamitsu T, Nakanishi T, Iizuka B, Okuda H, Obata H, Endoh K, Benno Y, Mitsuoka T. Intestinal microflora in cirrhotic patients and their changes after administration of Latamoxef in combination with drug-resistant Bifidobacterium longum. J Gastroenterol Hepatol. 1989;4 Suppl 1:287-8. PubMed PMID: 2519079. 15: Wilson SE. Cephalosporin therapy in intra-abdominal infection: comparative studies of cefotetan, latamoxef and cefoxitin. Chemioterapia. 1988 Aug;7(4):213-7. PubMed PMID: 3180298. 16: Ishida M, Kawamura K, Takekawa H, Takanashi S, Onodera K. [A case of pneumonitis due to latamoxef and tobramycin]. Nihon Kyobu Shikkan Gakkai Zasshi. 1988 Jul;26(7):756-9. Japanese. PubMed PMID: 3241513. 17: Viens P, Maraninchi D, Gaspard MH, Stoppa AM, Blaise D, Miquel M, Mannoni P, Carcassonne Y. [Randomized trial of empirical antibiotic therapy in febrile episodes after bone marrow transplantation. Comparison of an aminoglycoside-beta lactam (tobramycin-ticarcillin) combination with 2 beta-lactam antibiotics (ticarcillin-latamoxef)]. Pathol Biol (Paris). 1988 May;36(5):567-70. French. PubMed PMID: 3043359. 18: Kojima R, Ito M, Suzuki Y. Studies on the nephrotoxicity of aminoglycoside antibiotics and protection from these effects. (5). Interaction of tobramycin with latamoxef in vitro. J Pharmacobiodyn. 1988 Jan;11(1):9-17. PubMed PMID: 3385606. 19: Eng RH, Cherubin CE, Pechere JC, Beam TR Jr. Treatment failures of cefotaxime and latamoxef in meningitis caused by Enterobacter and Serratia spp. J Antimicrob Chemother. 1987 Dec;20(6):903-11. PubMed PMID: 3501999. 20: Chimura T, Sato S, Suzuki T, Ito K, Sumiyoshi Y, Kanasugi H, Nakakuki M, Abe Y, Banzai M. [Prophylactic effects of a combined use of a cephem antibiotic, latamoxef, and tobramycin on postoperative infection in obstetrics and gynecology]. Jpn J Antibiot. 1987 Jul;40(7):1253-8. Japanese. PubMed PMID: 3682180.